{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:37:22Z","timestamp":1747157842602,"version":"3.40.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clinthera.2024.04.006","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T19:25:25Z","timestamp":1717269925000},"page":"e107-e113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9544-6739","authenticated-orcid":false,"given":"Rafe","family":"Hunter Hall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carson L.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Griffin K.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andriana M.","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chase","family":"Ladd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"McIntire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Ferrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Tuia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matt","family":"Vassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.04.006_bib0001","unstructured":"Cancer.Net. Lung cancer - non-small cell - statistics. 2012. Accessed June 14, 2023. https:\/\/www.cancer.net\/cancer-types\/lung-cancer-non-small-cell\/statistics."},{"key":"10.1016\/j.clinthera.2024.04.006_bib0002","unstructured":"Center for Drug Evaluation, Research. FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations. U.S. Food and Drug Administration. Accessed May 17, 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr."},{"issue":"6","key":"10.1016\/j.clinthera.2024.04.006_bib0003","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.18632\/oncotarget.1891","article-title":"Molecular pathways and therapeutic targets in lung cancer","volume":"5","author":"Shtivelman","year":"2014","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.clinthera.2024.04.006_bib0004","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40273-021-01022-9","article-title":"Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatments for EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada","volume":"39","author":"Kim","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1016\/j.clinthera.2024.04.006_bib0005","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1093\/annonc\/mdv353","article-title":"Oncology 2020: a drug development and approval paradigm","volume":"26","author":"Dhingra","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clinthera.2024.04.006_bib0006","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/clpt.2009.293","article-title":"Deconstructing the drug development process: the new face of innovation","volume":"87","author":"Kaitin","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.clinthera.2024.04.006_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41571-019-0287-0","article-title":"Imatinib and the long tail of targeted drug development","volume":"17","author":"Carlisle","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinthera.2024.04.006_bib0008","first-page":"2","article-title":"Benefit, risk, and outcomes in drug development: A systematic review of Sunitinib","volume":"108","author":"Carlisle","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.clinthera.2024.04.006_bib0009","first-page":"1","article-title":"Open science framework (OSF)","volume":"105","author":"Foster","year":"2017","journal-title":"J. Med. Lib. Assoc."},{"key":"10.1016\/j.clinthera.2024.04.006_bib0010","unstructured":"Hughes G, McIntire R, Hightower B, et al. 06\/23 June projects: drug landscapes. 2023. Accessed June 23, 2023. https:\/\/osf.io\/vdr68\/?view_only=f4e632c6e7e241149e09e5e3a0ec946b."},{"issue":"2","key":"10.1016\/j.clinthera.2024.04.006_bib0011","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2024.04.006_bib0012","unstructured":"Common terminology criteria for adverse events (CTCAE). Cancer Therapy Evaluation Program (CTEP). (2021, April 19). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_60"},{"issue":"1","key":"10.1016\/j.clinthera.2024.04.006_bib0013","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"issue":"3","key":"10.1016\/j.clinthera.2024.04.006_bib0014","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(15)00540-9","article-title":"Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial","volume":"17","author":"Harbeck","year":"2016","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.clinthera.2024.04.006_bib0015","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clinthera.2024.04.006_bib0016","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clinthera.2024.04.006_bib0017","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/13543784.2014.924505","article-title":"Afatinib in the treatment of breast cancer","volume":"23","author":"Hurvitz","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.clinthera.2024.04.006_bib0018","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/annonc\/mdz060","article-title":"Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer","volume":"30","author":"Blumenthal","year":"2019","journal-title":"Ann Oncol"},{"issue":"9912","key":"10.1016\/j.clinthera.2024.04.006_bib0019","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(13)62229-1","article-title":"How to increase value and reduce waste when research priorities are set","volume":"383","author":"Chalmers","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.04.006_bib0020","unstructured":"Higgins J, Welch V. Cochrane Handbook for Systematic Reviews of Interventions. 1st ed. (Higgins J, Green S, eds.). John Wiley & Sons; 2011. Accessed June 19, 2023. http:\/\/www.training.cochrane.org\/handbook."},{"issue":"6957","key":"10.1016\/j.clinthera.2024.04.006_bib0021","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/bmj.309.6957.789","article-title":"Meta-analysis and its problems","volume":"309","author":"Eysenck","year":"1994","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.clinthera.2024.04.006_bib0022","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1188\/18.CJON.542-548","article-title":"Afatinib therapy: practical management of adverse events with an oral agent for non-small cell lung cancer treatment","volume":"22","author":"Edwards","year":"2018","journal-title":"Clin J Oncol Nurs"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824000870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T18:30:00Z","timestamp":1726857000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824000870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0149291824000870"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.04.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}